IL21R and B-cell chronic lymphocytic leukemia: IL-21 and IL-21R are emerging as promising targets for novel cytokine-based immunotherapies in many diseases, including SLE, primary immunodeficiency (PID), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and lymphoma (132–134).